You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

5195 Results
In October 2024, the Ontario Breast Screening Program lowered the starting age for screening from age 50 to age 40.This page provides breast cancer...
En octobre 2024, le Programme ontarien de dépistage du cancer du sein a abaissé l’âge de début du dépistage de 50 à 40 ans. Cette page fournit de l’...
Document
Dec 1969
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Trastuzumab Deruxtecan - Unresectable Locally Advanced or Metastatic Breast Cancer
New Drug Funding Program
    Trastuzumab Deruxtecan - HER2-low Unresectable Locally Advanced or Metastatic Breast Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
Enhertu trastuzumab deruxtecan
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
Enhertu trastuzumab deruxtecan (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Drug
Other Name(s): Enhertu®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Dec 1969
Drug
Other Name(s): Orgovyx®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Dec 1969
Regimen
Cancer Type:
Gastrointestinal, 
Gastric / Stomach
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Trastuzumab Deruxtecan - Previously Treated Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
Enhertu trastuzumab deruxtecan
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Our Comprehensive Cancer Biomarker Testing Program supports patient management through the testing of diagnostic, predictive and prognostic markers....

Pages